PT - JOURNAL ARTICLE AU - MIIKKA LEHTONEN AU - JORMA SORMUNEN AU - MARIE HJÄLM-ERIKSSON AU - CAMILLA THELLENBERG-KARLSSON AU - TEPPO HUTTUNEN AU - CLAES GINMAN AU - PIRKKO-LIISA KELLOKUMPU-LEHTINEN AU - On Behalf of the Investigators of the Scandinavian Prostate Cancer Group Study No 13 TI - Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study AID - 10.21873/anticanres.15460 DP - 2022 Jan 01 TA - Anticancer Research PG - 87--92 VI - 42 IP - 1 4099 - http://ar.iiarjournals.org/content/42/1/87.short 4100 - http://ar.iiarjournals.org/content/42/1/87.full SO - Anticancer Res2022 Jan 01; 42 AB - Background/Aim: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). Patients and Methods: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m2 (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. Results: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. Conclusion: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.